Report Overview

The global glaucoma therapeutics market size stood at around USD 6.59 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Glaucoma is one of the most common ophthalmic disorders that are encountered in secondary and primary care facilities and the third leading cause of blindness among the population. According to BrightFocus Foundation, glaucoma is prevalent in 3 million individuals in the U.S. and out of those, 2.7 million are aged more than 40 years. This slow progressing disorder is caused due to structural changes in the optical nerve causing blindness or varying levels of visual loss. The increasing pool of geriatric population and improving diagnostic tools to detect glaucoma are aiding the glaucoma therapeutics market growth.



Market Drivers

The increasing prevalence of glaucoma across the globe represents one of the key factors driving the growth of the market. Glaucoma is highly prevalent in patients with diabetes and other eye disorders, such as age-related macular degeneration (AMD), cataract and dry eye. In line with this, the rising geriatric population, which is more susceptible to such ailments, is creating a positive outlook for the market growth. Furthermore, increasing health consciousness among the masses and rising preference for laser glaucoma surgery is also driving the market growth.

Additionally, the development of innovative combination drugs is acting as another growth-inducing factor. Pharmaceutical manufacturers are creating anti-glaucoma drugs and prostaglandin analogs combined with two or more drugs to control the elevated levels of IOP. Other factors, including the advent of advanced glaucoma diagnostic techniques, along with improvements in the healthcare infrastructure, are anticipated to drive the market further. Looking forward, the publisher expects the global glaucoma therapeutics market to continue its moderate growth during the next five years.